Valsartan restores inflammatory response by macrophages in adipose and hepatic tissues of LPS-infused mice

Misaki Iwashita, Yusuke Nakatsu, Hideyuki Sakoda, Midori Fujishiro, Akifumi Kushiyama, Toshiaki Fukushima, Sonoko Kumamoto, Takanori Shinjo, Hideaki Kamata, Fusanori Nishimura, Tomoichiro Asano

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Inflammation involving adipose tissue is regarded as one of the major molecular mechanisms underlying obesity-related insulin resistance. Recent studies have suggested a series of angiotensin II receptor blockers (ARBs) to improve insulin resistance or protect against the development of diabetes mellitus. We previously demonstrated that valsartan suppresses the inflammatory response of macrophages. Interestingly, however, this effect did not occur via peroxisome proliferator-activated receptor (PPAR) γ or the AT1a receptor. This suppression appears to secondarily lead to amelioration of insulin resistance and reductions in abnormal gene expressions in adipocytes. In addition to these in γ vitro findings, we herein demonstrate the in vivo effects of valsartan, using mice constitutively infused with lipopolysaccharide (LPS) for 4 weeks. Oral administration of valsartan to LPS-infused mice normalized the increased expressions of inflammatory cytokines in adipose and liver tissues. These results raise the possibility that valsartan not only contributes to normalization of obesity-related insulin resistance, but is also beneficial for the treatment of other diseases with inflammation related to the metabolic syndrome such as atherosclerosis and non-alcoholic steatohepatitis. Further study is necessary to clarify these issues.

Original languageEnglish
Pages (from-to)28-32
Number of pages5
JournalAdipocyte
Volume2
Issue number1
DOIs
Publication statusPublished - Jan 1 2013

Fingerprint

Valsartan
Lipopolysaccharides
Insulin Resistance
Adipose Tissue
Macrophages
Liver
Obesity
Inflammation
Peroxisome Proliferator-Activated Receptors
Angiotensin Receptor Antagonists
Fatty Liver
Adipocytes
Oral Administration
Atherosclerosis
Diabetes Mellitus
Cytokines
Gene Expression

All Science Journal Classification (ASJC) codes

  • Histology
  • Cell Biology

Cite this

Iwashita, M., Nakatsu, Y., Sakoda, H., Fujishiro, M., Kushiyama, A., Fukushima, T., ... Asano, T. (2013). Valsartan restores inflammatory response by macrophages in adipose and hepatic tissues of LPS-infused mice. Adipocyte, 2(1), 28-32. https://doi.org/10.4161/adip.21837

Valsartan restores inflammatory response by macrophages in adipose and hepatic tissues of LPS-infused mice. / Iwashita, Misaki; Nakatsu, Yusuke; Sakoda, Hideyuki; Fujishiro, Midori; Kushiyama, Akifumi; Fukushima, Toshiaki; Kumamoto, Sonoko; Shinjo, Takanori; Kamata, Hideaki; Nishimura, Fusanori; Asano, Tomoichiro.

In: Adipocyte, Vol. 2, No. 1, 01.01.2013, p. 28-32.

Research output: Contribution to journalArticle

Iwashita, M, Nakatsu, Y, Sakoda, H, Fujishiro, M, Kushiyama, A, Fukushima, T, Kumamoto, S, Shinjo, T, Kamata, H, Nishimura, F & Asano, T 2013, 'Valsartan restores inflammatory response by macrophages in adipose and hepatic tissues of LPS-infused mice', Adipocyte, vol. 2, no. 1, pp. 28-32. https://doi.org/10.4161/adip.21837
Iwashita, Misaki ; Nakatsu, Yusuke ; Sakoda, Hideyuki ; Fujishiro, Midori ; Kushiyama, Akifumi ; Fukushima, Toshiaki ; Kumamoto, Sonoko ; Shinjo, Takanori ; Kamata, Hideaki ; Nishimura, Fusanori ; Asano, Tomoichiro. / Valsartan restores inflammatory response by macrophages in adipose and hepatic tissues of LPS-infused mice. In: Adipocyte. 2013 ; Vol. 2, No. 1. pp. 28-32.
@article{b017ed37c02e4c7db7ac99393b091269,
title = "Valsartan restores inflammatory response by macrophages in adipose and hepatic tissues of LPS-infused mice",
abstract = "Inflammation involving adipose tissue is regarded as one of the major molecular mechanisms underlying obesity-related insulin resistance. Recent studies have suggested a series of angiotensin II receptor blockers (ARBs) to improve insulin resistance or protect against the development of diabetes mellitus. We previously demonstrated that valsartan suppresses the inflammatory response of macrophages. Interestingly, however, this effect did not occur via peroxisome proliferator-activated receptor (PPAR) γ or the AT1a receptor. This suppression appears to secondarily lead to amelioration of insulin resistance and reductions in abnormal gene expressions in adipocytes. In addition to these in γ vitro findings, we herein demonstrate the in vivo effects of valsartan, using mice constitutively infused with lipopolysaccharide (LPS) for 4 weeks. Oral administration of valsartan to LPS-infused mice normalized the increased expressions of inflammatory cytokines in adipose and liver tissues. These results raise the possibility that valsartan not only contributes to normalization of obesity-related insulin resistance, but is also beneficial for the treatment of other diseases with inflammation related to the metabolic syndrome such as atherosclerosis and non-alcoholic steatohepatitis. Further study is necessary to clarify these issues.",
author = "Misaki Iwashita and Yusuke Nakatsu and Hideyuki Sakoda and Midori Fujishiro and Akifumi Kushiyama and Toshiaki Fukushima and Sonoko Kumamoto and Takanori Shinjo and Hideaki Kamata and Fusanori Nishimura and Tomoichiro Asano",
year = "2013",
month = "1",
day = "1",
doi = "10.4161/adip.21837",
language = "English",
volume = "2",
pages = "28--32",
journal = "Adipocyte",
issn = "2162-3945",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - Valsartan restores inflammatory response by macrophages in adipose and hepatic tissues of LPS-infused mice

AU - Iwashita, Misaki

AU - Nakatsu, Yusuke

AU - Sakoda, Hideyuki

AU - Fujishiro, Midori

AU - Kushiyama, Akifumi

AU - Fukushima, Toshiaki

AU - Kumamoto, Sonoko

AU - Shinjo, Takanori

AU - Kamata, Hideaki

AU - Nishimura, Fusanori

AU - Asano, Tomoichiro

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Inflammation involving adipose tissue is regarded as one of the major molecular mechanisms underlying obesity-related insulin resistance. Recent studies have suggested a series of angiotensin II receptor blockers (ARBs) to improve insulin resistance or protect against the development of diabetes mellitus. We previously demonstrated that valsartan suppresses the inflammatory response of macrophages. Interestingly, however, this effect did not occur via peroxisome proliferator-activated receptor (PPAR) γ or the AT1a receptor. This suppression appears to secondarily lead to amelioration of insulin resistance and reductions in abnormal gene expressions in adipocytes. In addition to these in γ vitro findings, we herein demonstrate the in vivo effects of valsartan, using mice constitutively infused with lipopolysaccharide (LPS) for 4 weeks. Oral administration of valsartan to LPS-infused mice normalized the increased expressions of inflammatory cytokines in adipose and liver tissues. These results raise the possibility that valsartan not only contributes to normalization of obesity-related insulin resistance, but is also beneficial for the treatment of other diseases with inflammation related to the metabolic syndrome such as atherosclerosis and non-alcoholic steatohepatitis. Further study is necessary to clarify these issues.

AB - Inflammation involving adipose tissue is regarded as one of the major molecular mechanisms underlying obesity-related insulin resistance. Recent studies have suggested a series of angiotensin II receptor blockers (ARBs) to improve insulin resistance or protect against the development of diabetes mellitus. We previously demonstrated that valsartan suppresses the inflammatory response of macrophages. Interestingly, however, this effect did not occur via peroxisome proliferator-activated receptor (PPAR) γ or the AT1a receptor. This suppression appears to secondarily lead to amelioration of insulin resistance and reductions in abnormal gene expressions in adipocytes. In addition to these in γ vitro findings, we herein demonstrate the in vivo effects of valsartan, using mice constitutively infused with lipopolysaccharide (LPS) for 4 weeks. Oral administration of valsartan to LPS-infused mice normalized the increased expressions of inflammatory cytokines in adipose and liver tissues. These results raise the possibility that valsartan not only contributes to normalization of obesity-related insulin resistance, but is also beneficial for the treatment of other diseases with inflammation related to the metabolic syndrome such as atherosclerosis and non-alcoholic steatohepatitis. Further study is necessary to clarify these issues.

UR - http://www.scopus.com/inward/record.url?scp=84904965332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904965332&partnerID=8YFLogxK

U2 - 10.4161/adip.21837

DO - 10.4161/adip.21837

M3 - Article

AN - SCOPUS:84904965332

VL - 2

SP - 28

EP - 32

JO - Adipocyte

JF - Adipocyte

SN - 2162-3945

IS - 1

ER -